Induction of cytotoxicity of human tumor-infiltrating lymphocytes against autologous tumor cells and its application for cancer therapy
Induction of cytotoxicity of human tumor-infiltrating lymphocytes against autologous tumor cells and its application for cancer therapy
批准号:
63570599
负责人:
HIZUTA Akio
金额:
$0.19万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1988
资助国家:
日本
项目状态:
已结题
起止时间:
1988 至 1989
中文摘要
点击翻译按钮获取中文摘要
英文摘要
1) Cancer patients were treated with the adoptive immunotherapy with lymphokine-activated killer (LAK) cells which were induced by culture of autologous peripheral blood lymphocytes (PBL) with interleukin-2(IL-2). Local administration by intraarterial or intracavital infusions of LAK cells produced a superior therapeutic efficacy to systemic administration by intravenous infusions.2)A half of tumor-infiltrating cells into human solid cancers consisted of T lymphocytes and the proportion of CD8^+T lymphocytes were greater than that of PBL.Tumor-infiltrating lymphocytes (TIL) contained gammadelta T cells and the majority of those cells in colorectal cancers were CD8^+ gammadelta T cells whose lineage was different from that of PBL.Hepatocellular carcinoma contained a greater number of gammadelta TIL than other human solid cancers.3)Culture of TIL with IL-2 alone was inadequate for their in vitro expansion, and we found that TIL effectively expanded in culture by addition of 20% conditioned medium derived from LAK cell induction.4)Cytotoxicity against tumor cells was notdetected in freshly isolated TIL.Cytotoxicity of TIL gradually increased in culture, reached its maximum at 2 to 3 weeks, and disappeared at 4 to 7 weeks. Phytohemagglutinin (PHA) was found to be capable of partial restoration of the diminished cytotoxicity of cultured TIL.5) TIL of advanced gastric cancer were activated in vivo by preoperative intratumoral injection with a biological response modifier, OK-432, and survival of patients after curative sugery was compared with control patients. Although there was no difference in survival of patients with scanty TIL,the activation of TIL improved 3-year survival in patients with TIL of a medium or over degree.
期刊论文(28)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Hizuta, A., Takahashi, M., Watanabe, N., Iwagaki, H., Tanaka, N., and Orita, K.: "Liver metastasis and local immune responses(in Japanese)" KARKINOS. 6. 307-313 (1993)
Hizuta, A.、Takahashi, M.、Watanabe, N.、Iwagaki, H.、Tanaka, N. 和 Orita, K.:“肝转移和局部免疫反应(日语)”KARKINOS。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Suo, J., Tanaka, N., Hizuta, A., Yunoki, S., and Orita, K.: "Suppression of hepatic natural killer activity by liver metastasis of cancer and restoration of killer activity by oral administration of a Basidomycetes-derived polysaccharide, PSK" Acta Medica
Suo, J.、Tanaka, N.、Hizuta, A.、Yunoki, S. 和 Orita, K.:“通过癌症肝转移抑制肝脏自然杀伤活性,并通过口服担子菌恢复杀伤活性 -
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
松本 三明: "腫瘍内浸潤リンパ球におけるγδT細胞の解析" 医学のあゆみ. 162. 159-160 (1992)
Mitsuaki Matsumoto:“肿瘤浸润淋巴细胞中 γδT 细胞的分析”医学史 162. 159-160 (1992)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
日伝 晶夫: "肝転移と肝局所免疫" KARKINOS. 6. 307-313 (1993)
Akio Niden:“肝转移和肝局部免疫”KARKINOS 6. 307-313 (1993)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hizuta A, Yunoki S, Tatemoto A, Okamoto Y, Nagata Y, et al.: "Frontiers of Mucosal Immunology" Tsuchiya M, Nagura H,Hibi T and Moro I, 2 (1991)
Hizuta A、Yunoki S、Tatemoto A、Okamoto Y、Nagata Y 等人:“粘膜免疫学前沿”Tsuchiya M、Nagura H、Hibi T 和 Moro I,2 (1991)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 28 条
Development of Differentiation-directed Cancer Gene Therapy with p21
-
批准号:09671310
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.3万
-
财政年份:1997
-
负责人:HIZUTA Akio
-
依托单位:
Gene Therapy for Colon Cancer with Adenoviral Vector Expressing Tumor Suppressor p53 Gene
-
批准号:07671393
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.47万
-
财政年份:1995
-
负责人:HIZUTA Akio
-
依托单位:
海外基金